An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila

Digestion

Volumn 100, Issue 2, 2019, Pages 127-138

  Cruz Aguliar, Rebeca M ^a   Wantia, Nina ^b   Clavel, Thomas ^c,f   Vehreschild, Maria J G T ^d   Buch, Thorsten ^e   Bajbouj, Monther ^a   Haller, Dirk ^c   Busch, Dirk ^b   Schmid, Roland M ^a   Stein Thoeringer, Christoph K ^a,g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Abdominal pain; Akkermansia muciniphila; Fecal microbiota transfer; Gut microbiome; Irritable bowel syndrome

Indexed keywords

CALGRANULIN; LOPERAMIDE; PICOSULFATE SODIUM; RIFAXIMIN; RNA 16S; BACTERIAL DNA;

ABDOMINAL PAIN; ADULT; AKKERMANSIA MUCINIPHILA; AMPLICON; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MICROBIOME; CLINICAL ARTICLE; COHORT ANALYSIS; COLONOSCOPY; ENGRAFTMENT; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; FEMALE; FLATULENCE; HUMAN; INTESTINE FLORA; INTESTINE PREPARATION; IRRITABLE COLON; MALE; MICROBIAL DIVERSITY; OBSERVATIONAL STUDY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36; SPECIES RICHNESS; STOOL DONOR; THERAPY EFFECT; TREATMENT OUTCOME; COMPLICATION; FECES; GENETICS; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MICROBIOLOGY; PAIN MEASUREMENT; PROCEDURES; VERRUCOMICROBIA; YOUNG ADULT;

ABDOMINAL PAIN; ADULT; DNA, BACTERIAL; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; RNA, RIBOSOMAL, 16S; TREATMENT OUTCOME; VERRUCOMICROBIA; YOUNG ADULT;

EID: 85056868293     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000494252     Document Type: Article

References (56)

1. Ford AC, Lacy BE, Talley NJ: Irritable bowel syndrome. N Engl J Med 2017; 376: 2566-2578.
2. Camilleri M: Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626-1635.
3. Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M: Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017; 152: 111-123.e8.
4. Rigsbee L, Agans R, Shankar V, Kenche H, Khamis HJ, Michail S, Paliy O: Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2012; 107: 1740-1751.
5. Shankar V, Homer D, Rigsbee L, Khamis HJ, Michail S, Raymer M, Reo NV, Paliy O: The networks of human gut microbe-metabolite associations are different between health and irritable bowel syndrome. ISME J 2015; 9: 1899-1903.
6. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM: Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801.
7. Jalanka J, Salonen A, Fuentes S, de Vos WM: Microbial signatures in post-infectious irritable bowel syndrome-toward patient stratification for improved diagnostics and treatment. Gut Microbes 2015; 6: 364-369.
8. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
9. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P: Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547-1561.
10. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG: A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75.e5.
11. Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K: A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: a randomized controlled trial. Gastroenterology 2017; 153: 936-947.
12. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG: Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015; 64: 93-100.
13. Bennet SMP, Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Öhman L, Simrén M: Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut 2018; 67: 872-881.
14. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
15. Narula N, Kassam Z, Yuan Y, Colombel JF, Ponsioen C, Reinisch W, Moayyedi P: Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 2017; 23: 1702-1709.
16. Bakker GJ, Nieuwdorp M: Fecal microbiota transplantation: therapeutic potential for a multitude of diseases beyond Clostridium difficile. Microbiol Spectr 2017; 5.
17. Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH: Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017; 46: 479-493.
18. Andrews PJ, Borody TJ: "Putting back the bugs": bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med J Aust 1993; 159: 633-634.
19. Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D: Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150: 604.
20. Pinn DM, Aroniadis OC, Brandt LJ: Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol 2014; 109: 1831-1832.
21. Mizuno S, Masaoka T, Naganuma M, Kishimoto T, Kitazawa M, Kurokawa S, Nakashima M, Takeshita K, Suda W, Mimura M, Hattori M, Kanai T: Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion 2017; 96: 29-38.
22. Holvoet T, Joossens M, Wang J, Boelens J, Verhasselt B, Laukens D, van Vlierberghe H, Hindryckx P, De Vos M, De Looze D, Raes J: Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut 2017; 66: 980-982.
23. Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R: Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018;3:17-24.
24. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH: Fecal microbiota transplantation induces remission in patients with Active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149: 102-109.e6.
25. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A: Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761-767.
26. Keshteli AH, Millan B, Madsen KL: Pretreatment with antibiotics may enhance the efficacy of fecal microbiota transplantation in ulcerative colitis: a meta-analysis. Mucosal Immunol 2017; 10: 565-566.
27. Bazanella M, Maier TV, Clavel T, Lagkouvardos I, Lucio M, Maldonado-Gòmez MX, Autran C, Walter J, Bode L, Schmitt-Kopplin P, Haller D: Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome. Am J Clin Nutr 2017; 106: 1274-1286.
28. Lagkouvardos I, Joseph D, Kapfhammer M, Giritli S, Horn M, Haller D, Clavel T: IMNGS: a comprehensive open resource of processed 16S rRNA microbial profiles for ecology and diversity studies. Sci Rep 2016; 6: 33721.
29. Lagkouvardos I, Fischer S, Kumar N, Clavel T: Rhea: a transparent and modular R pipeline for microbial profiling based on 16S rRNA gene amplicons. PeerJ 2017; 5:e2836.
30. Amouretti M, Le Pen C, Gaudin AF, Bommelaer G, Frexinos J, Ruszniewski P, Poynard T, Maurel F, Priol G, El Hasnaoui A: Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol 2006; 30: 241-246.
31. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-660.
32. Hopman WM, Berger C, Joseph L, Towheed T, VandenKerkhof E, Anastassiades T, Adachi JD, Ioannidis G, Brown JP, Hanley DA, Papadimitropoulos EA; CaMos Research Group: The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population. Qual Life Res 2006; 15: 527-536.
33. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C: Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12:R60.
34. Bauer E, Laczny CC, Magnusdottir S, Wilmes P, Thiele I: Phenotypic differentiation of gastrointestinal microbes is reflected in their encoded metabolic repertoires. Microbiome 2015; 3: 55.
35. Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hämäläinen AM, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, Lähdesmäki H, Huttenhower C, Gevers D, Cullen TW, Knip M; DIABIMMUNE Study Group, Xavier RJ: Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 2016; 165: 1551.
36. Halkjær SI, Boolsen AW, Günther S, Christensen AH, Petersen AM: Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol 2017; 23: 4112-4120.
37. Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM: Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 2018.
38. Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, Li Y: Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 2016; 16: 62.
39. Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J: Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 2016; 10: 387-394.
40. Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C: The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 67-77.
41. Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P: Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016; 352: 586-589.
42. Kassam Z, Lee CH, Yuan Y, Hunt RH: Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-508.
43. Sofi AA, Silverman AL, Khuder S, Garborg K, Westerink JM, Nawras A: Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scand J Gastroenterol 2013; 48: 266-273.
44. Derrien M, Vaughan EE, Plugge CM, de Vos WM: Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004; 54: 1469-1476.
45. Derrien M, Belzer C, de Vos WM: Akkermansia muciniphila and its role in regulating host functions. Microb Pathog 2017; 106: 171-181.
46. Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH: Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010; 105: 2420-2428.
47. Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, Baxter NT, Zhao L, Schloss PD, Martens EC, Eaton KA, Chen GY: NLRP6 protects Il10-/-mice from colitis by limiting colonization of Akkermansia muciniphila. Cell Rep 2017; 19: 2174.
48. Chen Y, Xiao S, Gong Z, Zhu X, Yang Q, Li Y, Gao S, Dong Y, Shi Z, Wang Y, Weng X, Li Q, Cai W, Qiang W: Wuji wan formula ameliorates diarrhea and disordered colonic motility in post-inflammation irritable bowel syndrome rats by modulating the gut microbiota. Front Microbiol 2017; 8: 2307.
49. Bolognini D, Tobin AB, Milligan G, Moss CE: The Pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol 2016; 89: 388-398.
50. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DM, Venema K, Brummer RJ: The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952.e76.
51. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD: Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013; 110: 9066-9071.
52. Cani PD, de Vos WM: Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 2017; 8: 1765.
53. Li ZY, Zhang N, Wen S, Zhang J, Sun XL, Fan XM, Sun YH: Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol 2017; 41: 459-465.
54. Elsenbruch S, Enck P: Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2015; 12: 472-485.
55. Andorsky RI, Goldner F: Colonic lavage solution (polyethylene glycol electrolyte lavage solution) as a treatment for chronic constipation: a double-blind, placebo-controlled study. Am J Gastroenterol 1990; 85: 261-265.
56. Acosta A, Camilleri M, Shin A, Linker Nord S, O'Neill J, Gray AV, Lueke AJ, Donato LJ, Burton DD, Szarka LA, Zinsmeister AR, Golden PL, Fodor A: Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 2016; 7: e173.